Selecting Titration Step Sizes and Adjustment Intervals

Why Step Size and Timing Must Be Chosen Together

A titration rule specifies how dose changes in response to an observation. Its practical performance also depends on how large each change is and how long the patient remains on that dose before the next adjustment. A large increase can move exposure rapidly toward a useful range, but it can also create an excessive transient exposure or response. An assessment made too soon may reflect only part of the previous dose change; another increase at that point can compound the transient.

The calculations below provide a model-based way to screen candidate increments and intervals. They are not universal clinical rules. The choice depends on the exposure and response metric used by the titration rule, the acceptable transient, the dosing regimen, and the model’s assumptions. In particular, repeated oral doses produce peak–trough fluctuations that a single smooth time constant does not fully describe.

Time Courses After a Dose Change

For a one-compartment model with first-order elimination, the elimination rate constant is \(k=\mathrm{CL}/V\), and the half-life is \(t_{1/2}=\ln(2)/k\). With repeated doses at a fixed interval \(\tau\), the concentration at a fixed point in the dosing cycle approaches its steady-state value geometrically. After \(m\) intervals, the fraction of the new steady-state change expressed is \(1-\exp(-km\tau)\), provided the doses and disposition are linear and unchanged apart from the dose amount. The remaining fraction is \(\exp(-km\tau)\).

This same expression describes the change from one steady-state dose to another at a fixed phase of the dosing cycle under linear pharmacokinetics: by superposition, the difference from the new steady state decays at the elimination rate. It does not mean that concentration is constant within an interval. Peak and trough concentrations can remain clinically important even when the interval-averaged or same-phase change is mostly expressed.

A common pharmacodynamic approximation is a first-order equilibration model. If the exposure has stabilized and the corresponding equilibrium response is \(R_{\mathrm{new}}\), then the response \(R(t)\) approaches it at rate \(k_{\mathrm{PD}}\). Its residual fraction is \(\exp(-k_{\mathrm{PD}}t)\), with response half-life \(\ln(2)/k_{\mathrm{PD}}\). If exposure itself is still changing, the PD input is not an immediate step to its new equilibrium value; the coupled time course must be considered.

Choosing a Dose Increment

A dose step should be evaluated against the change it is predicted to cause in a decision-relevant quantity: for example, steady-state exposure, a response measure, or a modeled safety endpoint. If exposure \(E\) is approximately proportional to dose in the local range, define the local slope \(g=\Delta E/\Delta D\). A prespecified maximum permitted exposure change \(\Delta E_{\max}\) then gives the screening constraint \(|\Delta D|\leq\Delta E_{\max}/|g|\). This is a model-based bound, not a claim that one fixed percentage increase is safe for all drugs or patients.

When dose proportionality is not credible, calculate the predicted change directly as \(E(D_{\mathrm{new}})-E(D_{\mathrm{old}})\) using the exposure model. A nonlinear dose–exposure or exposure–response relationship can make equal dose increments produce unequal changes in exposure or response. The step may also need to respect available strengths and rounding constraints, while ensuring the rounded dose still meets the modeled bound. The dose-optimization objectives and constraints established for the regimen remain relevant: a convenient increment is not justified if its predicted transient or steady-state consequences are unacceptable.

Combining PK Accumulation With PD Equilibration

When both exposure and response change over time, a useful simplified model represents the normalized exposure change \(C(t)\) as a first-order approach to its new level, and the normalized response change \(R(t)\) as a first-order equilibration toward \(C(t)\): \(dC/dt=k_{\mathrm{PK}}(1-C)\) and \(dR/dt=k_{\mathrm{PD}}(C-R)\), with \(C(0)=R(0)=0\). Here, 0 and 1 denote the old and new steady-state levels on normalized scales. This model assumes a linear PD link over the change considered, constant rate constants, and no extra delay or effect-site process beyond the stated PD equilibration. It is a smooth approximation to the exposure trajectory; a regimen with substantial peak–trough variation should be assessed with its actual dosing model.

The PK equation gives \(C(t)=1-\exp(-k_{\mathrm{PK}}t)\). To obtain the response, define the response deviation from its new equilibrium as \(Y(t)=R(t)-1\). Since 1 is constant, \(dY/dt=dR/dt=k_{\mathrm{PD}}(C-R)\). Substituting \(C(t)\) and solving the resulting linear equation gives the residual response fraction below. This derivation makes explicit that the response is driven by the changing exposure, not by an instantaneous jump to the new PD equilibrium.

When the two rate constants are equal to \(k\), the limiting residual is \((1+kt)\exp(-kt)\). These expressions can be used to check a stated residual-response criterion under the simplified model. They also show why simply taking the larger of the separate PK and PD settling times need not guarantee that the coupled response has settled: the PD response continues to lag while the exposure is moving.

Practical Checks, Alternatives, and Limitations

Before adopting an increment and interval, check that the calculation concerns the same metric used by the titration rule. A trough-based rule cannot be justified solely by a calculation for average exposure if peak–trough differences are material. Check the model’s dose proportionality in the proposed range, whether the half-life or clearance changes with dose or time, and whether the response model represents the endpoint and its delay. If relevant, simulate the exact dosing times, dose history, and observation times, and inspect both transient and steady-state predictions.

A useful diagnostic is to compare predicted and observed changes after a step at the intended assessment time. Persistent drift may indicate that the interval is too short, the assumed time constants are wrong, or the response model omits a delay. A response that changes much more or less than predicted can also indicate nonlinearity, dose-dependent disposition, adherence or administration differences, or measurement error. These patterns do not identify a cause by themselves; they signal that the simplified calculation should not be treated as sufficient evidence for the next step.

The principal alternative to half-life-based screening is a regimen-specific PK/PD simulation that predicts the exact metric at candidate assessment times. It can account for dose timing, peaks and troughs, nonlinear kinetics, covariates, and a nonlinear response model when these are supported by the available model. A simpler half-life calculation is transparent and useful for an initial screen, but can mislead when the assumptions are poor. Conversely, simulation is only as reliable as its structural assumptions and parameter values; more detail does not remove uncertainty.

Ultimately, step size and interval are separate design choices that interact. A smaller step may reduce the consequence of a transient overshoot but can require more adjustments; a longer interval can allow more of the exposure and response change to appear but may delay reaching a useful regimen. The selected choices should be justified against the objective and constraints of the titration rule, and checked over plausible model behavior rather than inferred from half-life alone.